Another special relationship? Interactions between health technology policies and health care systems in the United States and the United Kingdom

Journal of Health Politics, Policy and Law

Volumn 36, Issue 1, 2011, Pages 119-139

  Sampat, Bhaven ^a   Drummond, Michael ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COMPARATIVE STUDY; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; MASS COMMUNICATION; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; NATIONAL HEALTH SERVICE; ORGANIZATION; ORGANIZATION AND MANAGEMENT; UNITED KINGDOM; UNITED STATES;

BIOMEDICAL RESEARCH; BIOMEDICAL TECHNOLOGY; DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; GREAT BRITAIN; HEALTH POLICY; HUMANS; ORGANIZATIONAL CULTURE; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 79955507315     PISSN: 03616878     EISSN: 15271927     Source Type: Journal    
DOI: 10.1215/03616878-1191126     Document Type: Article

References (59)

1. Acemoglu, D., and L. Linn. 2004. Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry. Quarterly Journal of Economics 119 :1049 - 1090.
2. American College of Physicians. 2008. Information on Cost- Effectiveness: An Essential Product of a National Comparative Effectiveness Program. Annals of Internal Medicine 148 : 956 - 961.
3. Anderson, G. F., and J. P. Poullier. 1999. Health Spending, Access, and Outcomes: Trends in Industrialized Countries. Health Affairs 18 (3): 178 - 192.
4. Anderson, G. F., U. E. Reinhardt, P. S. Hussey, and V. Petrosyan. 2003. It's the Prices, Stupid: Why the United States Is So Different from Other Countries. Health Affairs 22 (3): 89 - 105.
5. Banta, D., and M. F. Drummond. 2009. Health Technology Assessment in the United Kingdom. International Journal of Health Technology Assessment in Health Care 25 (suppl. 1): 178 - 181.
6. Booth, Sir Christopher. 1989. Clinical Research. In Historical Perspectives on the Role of the MRC, ed. J. Austoker and L. Bryder, 205 - 242. Oxford: Oxford University Press.
7. Brookings Institution. 2009. Bending the Curve: Effective Steps to Address Long-Term Health Care Spending Growth. Washington, DC: Brookings Institution.
8. Bryan, S., S. Sofaer, T. Siegelberg, and M. Gold. 2009. Has the Time Come for Cost-Effectiveness Analysis in US Health Care? Health Economics, Policy, and Law 4 :425 - 443.
9. Bryder, L. 1989. Tuberculosis and the MRC. In Historical Perspectives on the Role of the MRC, ed. J. Austoker and L. Bryder, 1 - 22. Oxford: Oxford University Press.
10. Buxton, M. J., R. Acheson, N. Caine, S. Gibson, and B. S. O'Brien. 1985. Costs and Benefits of the Heart Transplant Programmes at Harefield and Papworth Hospitals. London: HMSO.
11. Callahan, D. 2009. Taming the Beloved Beast: How Medical Technology Costs Are Destroying Our Health Care System. Princeton, NJ: Princeton University Press.
12. Cockburn, I. M., and S. Stern. 2010. Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy. Capitalism and Society 5(1). www.bepress.com/cas/vol5/iss1/art1/.
13. Cook-Deegan, R., and M. McGeary. 2006. The Jewel in the Federal Crown? History, Politics, and the National Institutes of Health. In History and Health Policy in the United States: Putting the Past Back In, ed. R. A. Stevens, C. E. Rosenberg, and L. R. Burns. New Brunswick, NJ: Rutgers University Press.
14. Cutler, D. M. 2002. Equality, Effciency, and Market Fundamentals: The Dynamics of International Medical- Care Reform. Journal of Economic Literature 40:881 - 906.
15. Cutler, D. M. 2005. Your Money or Your Life: Strong Medicine for America's Health Care System. Oxford: Oxford University Press.
16. Cutler, D. M., and M. McClellan. 2001. Is Technological Change in Medicine Worth It? Health Affairs 20 (5): 11 - 29.
17. Donelan, K., R. J. Blendon, C. Schoen, K. Davis, and K. Binns. 1999. The Cost of Health System Change: Public Discontent in Five Nations. Health Affairs 18 (3): 206 - 216.
18. Drummond, M. F., and C. Sorenson. 2009. Can NICE Be Nicer? Value in Health 12:634 - 636.
19. Enthoven, A. C. 1978. Shattuck Lecture - Cutting Cost without Cutting the Quality of Care. New England Journal of Medicine 298 :1229 - 1238.
20. Fisher, E. S., J. P. Bynum, and J. S. Skinner. 2009. Slowing the Growth of Health Care Costs: Lessons from Regional Variation. New England Journal of Medicine 360 :849 - 852.
21. Fisher, E., D. E. Wennberg, T. A. Stukel, D. J. Gottlieb, F. L. Lucas, and E. L. Pinder. 2003. The Implications of Regional Variations in Medicare Spending. Part 2: Health Outcomes and Satisfaction with Care. Annals of Internal Medicine, February 18. www.annals.org/content/138/4/288.short.
22. Fojo, T., and C. Grady. 2009. How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. Journal of the National Cancer Institute 101 :1-5.
23. Gambardella, A. 1995. Science and Innovation. Cambridge: Cambridge University Press.
24. Gambardella, A., L. Orsenigo, and F. Pammolli. 2000. Global Competitiveness in Pharmaceuticals: A European Perspective. Report prepared for the European Commission's Directorate- General for Enterprise and Industry.
25. Garber, A. 2007. Watch Where You Cut! Cato Unbound.www.cato-unboundorg/2007/09/18/alangarber/watch-where-you-cut/
26. Grabowski, H. G., and Y. R. Wang. 2006. The Quantity and Quality of Worldwide New Drug Introductions, 1982 - 2003. Health Affairs 25 : 452-460.
27. Inglehart, J. K. 2009. Prioritizing Comparative- Effectiveness Research: IOM Recommendations. New England Journal of Medicine 361 : 325-328.
28. Kennedy, I. 2009. Appraising the Value of Innovation and Other Benefits: A Short Study for NICE. www.nice.org.uk/media/98F/5C/KennedyStudyFinalReport.pdf (accessed April 13, 2010).
29. Kim, M., R. J. Blendon, and J. M. Benson. 2001. How Interested Are Americans in New Medical Technologies? A Multicountry Comparison. Health Affairs 20 (5): 194-201.
30. Kohut, A., and B. Stokes. 2006. America against the World: How We Are Different and Why We Are Disliked. New York: Times Books.
31. Lichtenberg, F. R. 2005. The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from Fifty-two Countries, 1982 - 2001. International Journal of Health Care Finance and Economics 5 : 47-73.
32. Light, D. W. 2009. Global Drug Discovery: Europe Is Ahead. Health Affairs Web Exclusive 28:W969 - W977.
33. Luce, B., and R. Singer Cohen. 2009. Health Technology Assessment in the United States. International Journal of Technology Assessment in Health Care 25 (suppl. 1): 33 - 42.
34. Manning, W. G., J. P. Newhouse, N. Duan, E. B. Keeler, B. Benjamin, A. Liebowitz, M. S. Marquis, and J. Zwanziger. 1988. Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment. Santa Monica, CA: RAND Corporation.
35. Mason, A., M. Drummond, S. Ramsey, J. Campbell, and D. Raisch. 2009. A Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric? Journal of Clinical Oncology 28:3234-3238.
36. Mowery, D. C., R. R. Nelson, and B. R. Martin. 2010. Technology Policy and Global Warming: Why New Policy Models Are Needed (Or Why Putting New Wine in Old Bottles Won't Work). Research Policy 39 : 1011-1023.
37. Mowery, D., and B. Sampat. 2004. Universities and National Innovation Systems. In The Oxford Handbook of Innovation, ed. J. Fagerberg, D. Mowery, and R. Nelson. New York: Oxford University Press.
38. National Institute for Health and Clinical Excellence (NICE). 2007. www.nice.org.uk (accessed December 20, 2009).
39. National Institute for Health and Clinical Excellence (NICE). 2008. Guide to the Methods of Technology Appraisal. London: NICE.
40. Neumann, P. J. 2004. Using Cost- Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. New York: Oxford University Press.
41. Neumann, P. J. 2009. American Exceptionalism and American Health Care: Implications for the U.S. Debate on Cost-Effectiveness Analysis. OHE Briefing No. 47. London: Office of Health Economics.
42. Newhouse, J. P. 1992. Medical Care Costs: How Much Welfare Loss? Journal of Economic Perspectives 6 (3): 3-21.
43. Office of Life Sciences. 2009. Life Sciences Blueprint. July. London: Office of Life Sciences.
44. Organisation for Economic and Co-operative Development (OECD). 2009. Health Data 2009: Statistics and Indicators for Thirty Countries. www.oecd.org/health.
45. Orszag, P. R., and P. Ellis. 2007. The Challenge of Rising Health Care Costs: A View from the Congressional Budget Office. New England Journal of Medicine 357:1793-1795.
46. Payer, L. 1996. Medicine and Culture. Rev. ed. New York: Holt.
47. Pisano, Gary P. 2006. Science Business: The Promise, the Reality, and the Future of Biotech. Boston: Harvard Business School Press.
48. Rawlins, M., and A. J. Culyer. 2004. National Institute for Clinical Excellence and Its Value Judgments. BMJ 329:224 - 227.
49. Sampat, B. 2008. The Dismal Science, the Crown Jewel, and the Endless Frontier: An Economist's Perspective on the NIH. In The New Economics of Technology Policy, ed. D. Foray, 148-162. Northampton, MA: Elgar.
50. Sampat, B., and F. Lichtenberg. 2009. The Roles of the Public and Private Sectors in Pharmaceutical Innovation. Mimeo.
51. Sheldon, T. A., N. Cullum, D. Dawson, A. Lankshear, K. Lowson, I. Watt, P. West, D. Wright, and J. Wright. 2004. What's the Evidence That NICE Guidance Has Been Implemented? Results from a National Evaluation Using Time Series Analysis, Audit of Patients' Notes, and Interviews. BMJ 329:999.
52. Singer, P. 2009. Why We Must Ration Health Care. New York Times, July 15.
53. Sorenson, C., M. F. Drummond, P. Kanavos, and A. McGuire. 2008. National Institute for Health and Clinical Excellence (NICE): How Does It Work and What Are the Implications for the U.S.? Report for the National Pharmaceutical Council. Reston, VA. http://www.npcnow.org/Public/Research___Publications/Publications/pub_ebm/NICE__How_Does_It_Work_and_Implications_for_the_US.aspx?Research=1.
54. Starr, P. 1984. The Social Transformation of American Medicine : The Rise of a Sovereign Profession and the Making of a Vast Industry. New York: Basic Books.
55. Strickland, S. P. 1972. Politics, Science, and Dread Disease : A Short History of United States Medical Research Policy. Cambridge, MA: Harvard University Press.
56. Wall Street Journal. 2009. Of NICE and Men. Review and Outlook. Wall Street Journal, July 7.
57. Weisbrod, B. A. 1991. The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment. Journal of Economic Literature 29 : 523 - 552.
58. Wilensky, G. R. 2006. Developing a Center for Comparative Effectiveness Information. Health Affairs 2 5 : w572-w585.
59. Wilensky, G. R. 2008. Cost-Effectiveness Information: Yes, It's Important, but Keep It Separate, Please! Annals of Internal Medicine 148:967-968.